Showing results (51-60 of 129) with videos related to

Sort By:
Pageof 13
Clinical Case Reports|August 16, 2016
Successful treatment of aplastic anemia-paroxysmal nocturnal hemoglobinuria associated with eosinophilic fasciitis with matched unrelated donor allogeneic peripheral blood stem cell transplantationKoji Sasaki, Uday Popat, Preetesh Jain, et al.
NPJ Precision Oncology|November 21, 2025
Integrative profiling strategies to guide personalized therapy in mantle cell lymphoma: a pilot studyYang Liu, Holly A Hill, Yijing Li, et al.
Human Pathology|May 17, 2025
Optical genome mapping reveals diverse mechanisms of cyclin activation in mantle cell lymphomas lacking IGH::CCND1Guilin Tang, Preetesh Jain, Shimin Hu, et al.
Leukemia & Lymphoma|October 14, 2014
Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomesOhad Benjamini, Preetesh Jain, Long Trinh, et al.
Blood|April 27, 2013
Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalitiesPreetesh Jain, Hagop Kantarjian, Aziz Nazha, et al.
British Journal of Haematology|June 16, 2016
Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trialDai Chihara, Hagop Kantarjian, Susan O'Brien, et al.
Leukemia & Lymphoma|August 10, 2013
Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experienceOhad Benjamini, Hagop Kantarjian, Mary Beth Rios, et al.
The Lancet. Haematology|December 22, 2015
Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trialsPreetesh Jain, Hagop Kantarjian, Mona Lisa Alattar, et al.
Cancer|August 11, 2016
A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phaseKoichi Takahashi, Hagop M Kantarjian, Yulong Yang, et al.
Cancer|October 20, 2015
Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitorsKoji Sasaki, Hagop M Kantarjian, Preetesh Jain, et al.
Pageof 13